HomeAI · summaries
Storia in 2 fonti
It's BMS vs. Celgene investors once more after US appeals court revives lawsuit
A federal appeals court has overturned (PDF) the 2024 dismissal of a lawsuit filed by Celgene shareholders that accuses Bris | A U.S. appeals court has revived a lawsuit filed by Celgene shareholders that accuses Bristol Myers Squibb of slow-playing the approval of blood cancer drug Breyanzi to avoid paying out a more than $6 billion contingent value right.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
qz.com
Appeals court revives $6.7B lawsuit against Bristol Myers Squibb
A unanimous 3-judge panel ruled that UMB Bank had standing to represent former Celgene shareholders despite a procedural error in its appointment
- ·
fiercepharma.com
It's BMS vs. Celgene investors once more after US appeals court revives lawsuit
A federal appeals court has overturned (PDF) the 2024 dismissal of a lawsuit filed by Celgene shareholders that accuses Bris | A U.S. appeals court has revived a lawsuit filed by…